FDA Panel Rejects MDMA Therapy for PTSD

1 min read
Source: STAT
FDA Panel Rejects MDMA Therapy for PTSD
Photo: STAT
TL;DR

An FDA advisory panel voted 9-2 against approving MDMA for PTSD treatment, citing concerns over clinical trial methodology and therapist oversight, and 10-1 against the benefits outweighing the risks under the proposed REMS program.

Share this article

Want the full story? Read the original reporting

Read on STAT